

Ali Amid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921967/publications.pdf>

Version: 2024-02-01

26
papers

605
citations

840119

11
h-index

713013

21
g-index

27
all docs

27
docs citations

27
times ranked

766
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing transfusion therapy for survivors of Haemoglobin Bart's hydrops fetalis syndrome: Defining the targets for α-haemoglobin fraction and α-functional-haemoglobin level. British Journal of Haematology, 2022, 197, 373-376.	1.2	4
2	Outcomes of haemoglobin Bart's hydrops fetalis following intrauterine transfusion in Ontario, Canada. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 51-56.	1.4	9
3	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematology, 2021, 8, e22-e33.	2.2	82
4	Immune tolerance induction using Fc fusion protein recombinant factor IX in severe haemophilia B. Haemophilia, 2021, 27, e776-e779.	1.0	0
5	Consensus statement for the perinatal management of patients with \pm thalassemia major. Blood Advances, 2021, 5, 5636-5639.	2.5	6
6	COVID Vaccination Rates in Children and Adults with Sickle Cell Disease in British Columbia, Canada. Blood, 2021, 138, 3034-3034.	0.6	3
7	Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy. Neurology, 2020, 94, 538-540.	1.5	2
8	Outcomes and risk factors of massive and submassive pulmonary embolism in children: a retrospective cohort study. Lancet Haematology, 2019, 6, e144-e153.	2.2	37
9	Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload. Acta Haematologica, 2019, 141, 256-260.	0.7	2
10	Iron overload in transfusion-dependent survivors of hemoglobin Bart's hydrops fetalis. Haematologica, 2018, 103, e184-e187.	1.7	8
11	Optimizing chronic transfusion therapy for survivors of hemoglobin Barts hydrops fetalis. Blood, 2016, 127, 1208-1211.	0.6	16
12	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study. Blood, 2016, 128, 3633-3633.	0.6	15
13	Hb S β -thalassemia due to Hb sickle and a novel deletion of DNase I hypersensitive sites HS3 and HS4 of the β locus control region. Haematologica, 2015, 100, e166-e168.	1.7	6
14	Presentation of Central Nervous System Tumors. , 2015, , 3-7.		1
15	Multi-label Classification of Anemia Patients. , 2015, , .		12
16	Screening for Thalassemia Carriers in Populations with a High Rate of Iron Deficiency: Revisiting the Applicability of the Mentzer Index and the Effect of Iron Deficiency on Hb A ₂ Levels. Hemoglobin, 2015, 39, 141-143.	0.4	8
17	Thalassaemia in children: from quality of care to quality of life. Archives of Disease in Childhood, 2015, 100, 1051-1057.	1.0	22
18	Improving Outcomes in Children with Sickle Cell Disease: Treatment Considerations and Strategies. Paediatric Drugs, 2014, 16, 255-266.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Compound Heterozygosity for Hb S and a Novel Deletion of Dnase I Hypersensitivity Sites HS3 and HS4 of β^2 -Globin Locus Control Region Results in Hb S/ β^2 -Thalassemia Phenotype. <i>Blood</i> , 2014, 124, 2692-2692.	0.6	0
20	Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1671-1675.	0.8	13
21	Evans Syndrome Secondary to HIV Infection. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 491.	0.3	0
22	Evans Syndrome Secondary to HIV Infection. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 490.	0.3	4
23	Thalassemia in Iran. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 233-238.	0.3	181
24	International Medical Response to a Natural Disaster: Lessons Learned from the Bam Earthquake Experience. <i>Prehospital and Disaster Medicine</i> , 2006, 21, 141-147.	0.7	115
25	Factor XIII deficiency in south-east Iran. <i>Haemophilia</i> , 2004, 10, 470-472.	1.0	19
26	An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates. <i>Clinical Biochemistry</i> , 2004, 37, 241-244.	0.8	26